

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA ozanimod for treating moderately to severely active  
ulcerative colitis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

The following comments were raised in the equality section of the consultation comments:

- There is inequality of access based on postcode, as some clinical commissioning groups do not fund later lines of therapy whereas others do
- A request that the company provide more detail on the management of people over the age of 55
- A comment that the mode of administration (oral) may reduce the need for travel to hospital and therefore be a benefit for: people with disability, people “in cultures where it may be harder to speak openly about the condition” or people living in remote areas
- Some treatments attract prescription costs which may cause a barrier to treatment for some people

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Inequality of access based on postcode, or cost of prescriptions, do not directly cover protected characteristic groups.

The stakeholder comment on age does not include a specific comment on any equalities issue.

The benefits of an oral treatment for protected characteristic groups should be considered by the committee, particularly if the most relevant comparator/s are not oral.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change necessary.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name): Henry Edwards**

**Date:** 27/10/21